New Releases from NCBI BookshelfCemiplimab (Libtayo): Therapeutic area: Locally advanced or metastatic non–small cell lung cancer (first line): CADTH Reimbursement Review [Internet].Cemiplimab (Libtayo): Therapeutic area: Locally advanced or metastatic non–small cell lung cancer (first line): CADTH Reimbursement Review [Internet].By / October 24, 2024 Post Content
